Background Waldenström's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic
lymphoma (LPL). The underlying mutation in this disorder has not been delineated. …

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for
which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy …

As populations age, heart failure (HF) is becoming increasingly common, and in addition to
a high burden of morbidity and mortality, HF has an enormous financial impact. Though …

Next-generation sequencing has revealed recurring somatic mutations in Waldenström
macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A (17%), …

Purpose We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in
patients with symptomatic, untreated Waldenström macroglobulinemia (WM). Patients and …

Background MYD88 L265P and CXCR4 WHIM mutations are highly prevalent in Waldenström’s
macroglobulinemia. MYD88 L265P triggers tumor-cell growth through Bruton’s tyrosine …

The genetic basis for Waldenström macroglobulinemia (WM) remains to be clarified. Although
6q losses are commonly present, recurring gene losses in this region remain to be defined…

By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88
L265P) that stimulates nuclear factor κB activity and is present in >90% of Waldenström …

Myeloid differentiation factor 88 (MYD88) L265P somatic mutation is highly prevalent in
Waldenström macroglobulinemia (WM) and supports malignant growth through nuclear factor κB …

Purpose Nucleoside analogs (NAs) are considered as appropriate agents in the treatment of
Waldenström macroglobulinemia (WM), a lymphoplasmacytic lymphoma. Sporadic reports …